Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Leukemia, Myeloid, Acute 3Lymphoma, Non-Hodgkin 2Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Upper Tract Urothelial Carcinomas 1Solid Tumors 1Serous Ovarian Cancer 1Recurrence 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Ovarian Neoplasms 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Amyloidosis 1

Interventions

HhAntag691 11sonidegib 5cemiplimab 5methyl 5-aminolevulinate 4daromun 4Imiquimod 3IPI-926 3gusacitinib 2Photochemotherapy 2Drug Evaluation 23-ingenyl angelate 2tozuleristide 1silmitasertib 1pembrolizumab 1TAK-441 1NVP-LEQ506 1MAPRE1 protein, human 1Intravital Microscopy 1Interleukin-2 1Injections 1IFL protocol 1Folfox protocol 1Capecitabine 1Bevacizumab 1BO-112 1BMS-833923 1BF-200 ALA 1Ascorbic Acid 1Aminolevulinic Acid 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Basal Cell × Drug Evaluation × Clear all
NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PellePharm, Inc.

Phase 2 Completed
17 enrolled 22 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

PellePharm, Inc.

Phase 2 Completed
36 enrolled 17 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡